Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive) and Purpose of Solution (Medication Replacemen

Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive) and Purpose of Solution (Medication Replacement and Medication Augmentation)

Chronic disorders, such as arthritis, diabetes, cancer, obesity and heart disease, are considered to be the leading causes of death and disability across the world. Specifically, the global prevalence of diabetes is estimated to be more than 300 million adults by 2025. According to the WHO, more than 450 million people are presently suffering from some form of mental health disorder (such as anxiety and depression), and / or neurological disorder. , , The rise in number of patients suffering from such clinical conditions continues to impose a significant burden on the global healthcare system. Specifically, in the US, it was estimated that approximately 90% of the country’s annual healthcare expenditure was on patients suffering from various chronic and mental health conditions.

Digital health solutions represent a relatively new concept, which was introduced into mainstream healthcare a few years ago. Such solutions are presently believed to possess the potential to reshape the practice of healthcare. Typically, digital therapeutics are available in the form of various types of gamified solutions, and / or standalone software applications, sometimes featuring active, personalized coaching support, or artificial intelligence (AI) enabled support. The ongoing COVID-19 pandemic and the mandatory enforcement of social distancing measures have created a significant demand for remote healthcare solutions. In fact, China introduced a range of digital solutions throughout different stages of the outbreak, immediately after the coronavirus spread. Recently, the USFDA also issued certain guidelines on usability of digital therapeutics (specifically for psychiatric conditions), allowing patients to receive treatment at home, minimizing visits to clinics / hospitals, thereby, reducing risk of exposure to the novel coronavirus. Moreover, several companies are actively striving to create and launch solutions that not only allow patients to diagnose and confirm disease symptoms, and consult with doctors / physicians remotely, but also offer therapeutic aid. Although the focus of such companies is presently on diabetes, mental health disorders and musculoskeletal injuries, experts believe that digital therapeutics may eventually replace / augment traditional treatment measures, with clinically validated software. ,

It is worth noting that there are several successful start-ups focused on designing and development of digital therapeutics; in fact, most such companies are backed by noteworthy investors. A number of digital health solutions are already in the market, and several other innovative solutions are under development. It is worth highlighting that for certain digital health solutions, reimbursement options are also available. In addition, several companies are focused on expanding their offerings to support the management of the COVID-19 pandemic. As the demand for digital solutions gradually rises, pioneers in this domain are likely to benefit the most from increased product sales.

The “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation))” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of digital therapeutics solutions (either commercialized or under development) in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

An overview of the current market landscape of digital therapeutic solutions, including information on status of development, type of solution (combination offering of software application + device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target indication(s), therapeutic area(s), and target population. In addition, it presents details of the companies developing digital therapeutic solution, highlighting year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.

An in depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of digital therapeutic solutions based on the parameters, such as product portfolio strength, number of target indication(s) and company size, [B] a grid representation illustrating the distribution of the digital therapeutic solutions based on status of development, type of solution and therapeutic area, [C] an insightful tree map representation of the digital therapeutic solutions, distributed on the basis of therapeutic area and company size, and [D] a world map representation highlighting the regional distribution of developer companies.

A detailed product competitiveness analysis of digital therapeutic solutions developed / under development for the most popular therapeutic areas taking into consideration the strength of product portfolio (based on the total number of digital therapeutic solutions being developed in that disease area) and key product specific parameters, such as status of development, type of solution, type of therapy, and purpose of solution.

Elaborate profiles of prominent small-sized and mid-sized players that are either engaged in the development or have developed digital therapeutic solutions. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.

A detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, highlighting leading sponsors and leading digital therapeutic solutions (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for trials initiated since 2018 for popular therapeutic areas).

An analysis of the investments made in the period between 2009 and 2020 (till June), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field.

An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2008 and 2020 (till May), covering marketing and distribution agreements, mergers / acquisitions, pilot product offerings, product / technology integration agreements, product / technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, research and development agreements and product development and commercialization agreements.

A detailed analysis of the various business models and go-to-market strategies adopted by companies involved in this space, providing details on various channels adopted / being adopted by stakeholders in the industry to raise awareness and offer access to their proprietary products.

A Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and different features of their products.

An insightful discussion on the impact of COVID-19 pandemic on the overall digital therapeutic solutions market, and the key initiatives undertaken by big pharma players.

A review of the key aspects related to the remote digital monitoring and diagnostics solutions, including [A] a brief introduction to remote digital monitoring and diagnostics solutions, highlighting the key benefits and roadblocks [B] an assessment of the market landscape of remote digital monitoring and diagnostics solutions, based on various parameters, such as status of development, type of solution, target disease indication(s) and therapeutic area, along with details on the companies that develop these solutions, highlighting year of establishment, company size and location of headquarters [C] detailed profiles of some of the key players that presently offer digital monitoring / diagnostic solutions for chronic disease management; each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters, lead investors, key partners and members of the executive team), details of their product portfolio, recent developments and an informed future outlook, and [D] an insightful analysis on various capital investments that have been made into the digital monitoring / diagnostics domain.

A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutic solutions industry.

An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions, indicating the increasing popularity of this domain. Furthermore, it highlights the potential future opportunities for players engaged in development of such solutions.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for digital therapeutics developers over the next decade. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within digital therapeutics market across [A] type of solution (combination offering of software application + device or AI or personal coach, and standalone software applications), [B] purpose of solution (medication replacement and medication augmentation), [C] type of therapy (curative and preventive), [D] distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), [E] therapeutic areas (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and [F] key geographical regions (North America (the US and Canada), Europe (France, Germany, Italy, Spain and the UK), Asia-Pacific (Australia, China, India, Japan, and South Korea) and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
Adam Kaufman (Chief Executive Officer, Canary Health)
Vijay Ravindran (Chief Executive Officer, Floreo)
Eran Ofir (Chief Executive Officer, Somatix)
Edouard Gasser (Chief Executive Officer, Tilak Healthcare)
Palakh R Sarogi (Vice President Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
Amelie Janson (Communication Manager, Voluntis)
Anonymous (Founder and Chief Executive Officer, UK based Small-Sized Company)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
Who are the leading developers offering digital therapeutic solutions?
What are the most popular therapeutic areas for digital therapeutic solutions?
Which companies are actively involved in conducting clinical trials for their solutions?
What are the key factors influencing the price of digital therapeutic solutions?
What is the trend in capital investments in the digital therapeutics market?
Which partnership models are commonly adopted by stakeholders in this industry?
What type of marketing strategies are being adopted by developers in this domain?
What is the impact of COVID-19 outbreak on digital therapeutic solutions market?
What are the opportunities for digital therapeutic solutions in emerging markets?
How is the current and future opportunity likely to be distributed across key market segments?
What are the anticipated future trends related to digital therapeutic solutions market?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of digital therapeutic solutions market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general overview of the digital health sector, covering details related to the current and future trends in the domain. The chapter highlights the key concepts related to digital therapeutics. It also features a discussion on strategic initiatives undertaken by several organizations to support the development of digital solutions for treatment of chronic disorders. The chapter also provides an overview of the various product development pathways adopted by the companies in this field.

Chapter 4 includes a detailed analysis of the current market landscape of over 230 digital therapeutic solutions, based on status of development, type of solution (combination offering of software application + device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target disease indication(s), therapeutic area(s), and target population. Further, the chapter provides an analysis of digital therapeutic solution developers, based on year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters. It also highlights the contemporary market trends in four schematic representations, which include [A] a bubble analysis comparing the leading players engaged in the development of digital therapeutic solutions based on the parameters, such as product portfolio strength, number of target indication(s) and company size, [B] a grid representation illustrating the distribution of the digital therapeutic solutions based on status of development, type of solution and therapeutic area, [C] an insightful tree map representation of the digital therapeutic solutions, distributed on the basis of therapeutic area and company size, and [D] a world map representation highlighting the regional distribution of developer companies.

Chapter 5 presents a detailed product competitiveness analysis of digital therapeutic solutions developed / under development for the most popular therapeutic areas taking into consideration the strength of product portfolio (based on the total number of digital therapeutic solutions being developed in that disease area) and key product specific parameters, such as status of development, type of solution, type of therapy, and purpose of solution.

Chapter 6 features elaborate profiles of prominent small-sized and mid-sized players that are either engaged in the development or have developed digital therapeutic solutions. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 7 provides a detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, highlighting leading sponsors and leading digital therapeutic solutions (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for trials initiated since 2018 for popular therapeutic areas).

Chapter 8 features an analysis of the investments made in the period between 2009 and 2020 (till June), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 9 features an in-depth analysis and discussion on the various partnerships inked between the players in this market, during the period, 2008-2020 (till May), covering marketing and distribution agreements, mergers / acquisitions, pilot product offerings, product / technology integration agreements, product / technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, research and development agreements and product development and commercialization agreements.

Chapter 10 features a detailed analysis on the various business models and go-to-market strategies adopted by companies involved in this space. It also provides details on various channels adopted / being adopted by stakeholders in the industry to raise awareness and offer access to their proprietary products.

Chapter 11 presents a Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and different features of their products.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of digital therapeutic solutions market till 2030. We have segmented the market across [A] type of solution (combination offering of software application + device or AI or personal coach, and standalone software applications), [B] purpose of solution (medication replacement and medication augmentation), [C] type of therapy (curative and preventive), [D] distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), [E] therapeutic areas (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and [F] key geographical regions (North America (the US and Canada), Europe (France, Germany, Italy, Spain and the UK), Asia-Pacific (Australia, China, India, Japan, and South Korea) and rest of the world).

Chapter 13 highlights the impact of COVID-19 outbreak on the overall digital therapeutics market. In addition, it features a brief discussion on the key initiatives undertaken by big pharma players.

Chapter 14 features a review of the of the key aspects related to the remote digital monitoring and diagnostics solutions, including [A] a brief introduction to remote digital monitoring and diagnostics solutions, highlighting the key benefits and roadblocks [B] an assessment of the market landscape of remote digital monitoring and diagnostics solutions, based on various parameters, such as status of development, type of solution, target disease indication(s) and therapeutic area, along with the details on the companies that develop these solutions, highlighting year of establishment, company size and location of headquarters [C] detailed profiles of some of the key players that presently offer digital monitoring / diagnostic solutions for chronic disease management; each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters, lead investors, key partners and members of the executive team), details of their product portfolio, recent developments and an informed future outlook, and [D] an insightful analysis on various capital investments that have been made into the digital monitoring / diagnostics domain.

Chapter 15 presents a discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutic solutions industry.

Chapter 16 offers an informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions, indicating the increasing popularity of this domain. Furthermore, it highlights the potential future opportunities for players engaged in the development of such solutions.

Chapter 17 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health), Adam Kaufman (Chief Executive Officer, Canary Health), Vijay Ravindran (Chief Executive Officer, Floreo), Eran Ofir (Chief Executive Officer, Somatix), Edouard Gasser (Chief Executive Officer, Tilak Healthcare), Palakh R Sarogi (Vice President Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics), Amelie Janson (Communication Manager, Voluntis), and Anonymous (Founder and Chief Executive Officer, UK based Small-Sized Company).

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix, which contains the list of companies and organizations mentioned in the report

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.

1. 23andMe
2. 2breathe Technologies
3. 2Morrow
4. 3.life
5. 30Ventures
6. 3M Ventures
7. 500 Startups
8. 5AM Ventures
9. 7wire Ventures
10. 98point6
11. A Better Weigh
12. AARDEX
13. Abbott
14. AbbVie
15. Aberdare Ventures
16. ACC
17. Accel Diagnostics
18. Accolade
19. Adage Capital Management
20. Adams Street Partners
21. Advanced Circulatory Systems
22. Advantage Consumer Healthcare
23. AET Fund
24. Aetna
25. Afterbook
26. Agro Group International Holdings
27. AIMMED
28. Airbus
29. Akili Interactive
30. Al-Ahli Hospital
31. Alex therapeutics
32. Alexandria Venture Investments
33. Alfvén & Didrikson
34. AliveCor
35. All4Life
36. Allen & Company
37. Alsace Business Angels
38. AltaMed
39. Amalgam
40. Amar Seva Sangam
41. AME Cloud Partners
42. American Association of Diabetes Educators
43. American Diabetes Association
44. American Society of Mechanical Engineers
45. American Telemedicine Association
46. Amgen Venture
47. Amiko Digital Health
48. Ampersand Health
49. Ana Health
50. Andreessen Horowitz
51. Anorak Ventures
52. Anthem
53. Aperture Venture Partners
54. Aplastic Anemia & MDS International Foundation
55. Apple
56. AppliedVR
57. Apricity Health
58. Arab Angel
59. Arboretum Ventures
60. Areta Health
61. Argon Global Healthcare
62. Arthritis New Zealand
63. Arthro Therapeutics
64. Asabys Partners
65. Ascensia Diabetes Care
66. Ascension Brighton Center for Recovery
67. Ascension Brighton Center for Recovery
68. ascure STEPS
69. Aspect Ventures
70. Association of Municipalities of Ontario
71. Astellas Pharma
72. Asthma and Allergy Foundation of America
73. AstraZeneca
74. AT&T
75. Athelas
76. ATX Therapeutics
77. Australasian College of Behavioural Optometrists (ACBO)
78. Autism Learning Partners
79. Axess4you
80. BackerNation
81. Baillie Gifford
82. Balderton Capital
83. Banco Sabadell
84. Baseline Ventures
85. Bayer
86. Bayer G4A
87. Beats Medical
88. Beaumont Hospital
89. BeCareLink
90. Beehive Holdings
91. BEENEXT
92. BehaVr
93. BeHealth Solutions
94. BeneTalk
95. Beneufit
96. Berger & Moore Advisors
97. Berklee's Institute for Creative Entrepreneurship
98. Bessemer Venture Partners
99. Beta Wave Consulting
100. Betr Health
101. Better Therapeutics
102. Betterise
103. Betterise Health Tech
104. Beyond Next Ventures
105. Big Health
106. Bigpoint
107. Bimark
108. BIOCORP
109. Bioepic
110. Biomark
111. BioSerenity
112. BioTrak Therapeutics
113. Biotricity
114. BioVentures Investors
115. Birla Institute of Technology and Science
116. BJC Healthcare
117. Blackbird Ventures
118. bLife
119. Bloom Burton
120. Blue Cross Blue Shield Venture Partners
121. Blue Mesa Health
122. Blue Note therapeutics
123. Blue Shield of California
124. Blue Spark Technologies
125. Blueprint Health
126. BOC Healthcare
127. Bodyport
128. Bold Health
129. Bonit Capital
130. Bose Ventures
131. Boston Medical Center
132. Boston University
133. Boulder Care
134. Bpifrance Large Venture
135. Brain Power
136. BrainCheck
137. Brainmarc
138. Breastlink
139. Breed Reply
140. BreezoMeter
141. Breyer Capital
142. Bridge Builders Collaborative
143. Brilliant & Company
144. Bristol-Myers Squibb
145. Broadway Video Ventures
146. Brooklands Capital Strategies
147. BSdp
148. Burrill & Company
149. Burst IQ
150. Burston
151. Business Development Bank of Canada
152. Business Health Care Group
153. Caffeinated Capital
154. Caixa Capital Micro II
155. Caixa Capital TIC II
156. Cambia Health Solutions
157. Canaan Partners
158. Canary Health
159. Cancer Research Collaboration (CRC)
160. Canepa Advanced Healthcare Fund
161. Canvas Ventures
162. CapDecisif Management
163. Capricorn ICT Arkiv
164. CareFirst
165. Carrot Health
166. Cascade Centers
167. Caspar
168. Castlight Health
169. Catasys
170. Cavendish Global
171. CAVU Venture Partners
172. Cedars-Sinai Medical Center
173. Celebrate the Children
174. Celgene
175. CellScope
176. Center for Autism Research (CAR)
177. Center for Managing Chronic Disease, University of Michigan
178. Center for the Advancement of Science in Space
179. Central Illinois Angels
180. Centria Healthcare
181. Centria Healthcare Autism Services
182. CF Hero
183. CheckUp & Choices
184. Chester County Intermediate Unit
185. Chibagin Capital
186. Chicago Ventures
187. Children’s Community Health Plan
188. Children’s Hospital of Philadelphia Center for Autism Research
189. Children's Hospital of Philadelphia
190. Cigna
191. Cigna Ventures
192. Cipla
193. CIS Agriferts
194. City Light Capital
195. Civilization Ventures
196. Claritas MindSciences
197. CleanSlate Research and Education Foundation
198. Click Therapeutics
199. Clinakos
200. CLSA
201. CM-CIC Innovation
202. Cognivive
203. Cognoa
204. Cohan Veteran’s Bioscience
205. COLOPL VR Fund
206. Columbia University Medical Center
207. Columbia University Medical Center
208. Community College System of New Hampshire
209. Community Health Network of Connecticut
210. Company K Partners
211. Compassware
212. Competitive Health
213. Comprehensive Pain Specialists
214. Connecticut Innovations
215. CoreHealth Technologies
216. Correlation Ventures
217. COWEN
218. CPS Capital Group
219. CRCM Ventures
220. Creandum
221. Crista Galli Ventures
222. Crohn's & Colitis Foundation
223. Crossroads Treatment Centers
224. CUCO Health
225. Cue
226. CureApp
227. Currae Healthtech
228. CVS Health
229. Cyberdine
230. Cyrcadia Asia
231. Cyrcadia Health
232. dacadoo
233. Dacuda
234. Dai-ichi Life
235. DAK Gesundheit
236. DancingMind
237. DaneVest Tech Fund
238. Dartmouth College
239. Data Collective
240. David Benshoof Klein
241. daVinci Digital Therapeutics
242. DCM
243. Deerfield Management
244. Delivering Scientific Innovation for Autism
245. Dendera Ventures
246. Dentsu Ventures
247. Department of Veteran Affairs
248. Dexcom
249. DG Ventures
250. Didriksons
251. Digbi Health
252. Digital Health
253. Digitalis
254. Digithera
255. DigiTx Partners
256. dLife
257. DN Capital
258. Doctor on Demand
259. Doctoriya
260. Doha Tech Angels
261. Draper Fisher Jurvetson
262. DrChrono
263. Dreamit Ventures
264. dreem
265. Droobi Health
266. dRx Capital
267. Dthera Sciences
268. dThx – Digital Therapeutics
269. DTM
270. Duke University School of Medicine
271. Early Signal
272. Echo Health Ventures
273. eClinicalHealth
274. Eco-Fusion
275. EDBI
276. Ehave
277. Electric Lime
278. Electronics and Telecommunication Research Institute (ETRI)
279. Elevation Capital
280. Eli Lilly
281. Ellume
282. Embr Labs
283. Emory University
284. Empatica
285. Empire Capital Partners
286. Endeavor Catalyst
287. Endotronix
288. Essex Woodlands
289. European Commission
290. European Pain Federation
291. European School on Interdisciplinary Tinnitus Research
292. Eva Ventures
293. EVERSANA
294. evivecare
295. Evolve Foundation
296. Excel Venture Management
297. Exosystems
298. Facebook
299. Fearless Ventures
300. Felicis Ventures
301. Ferrer
302. Fifty Years
303. Finnish Student Health System (FSHS)
304. FireStarter Fund
305. FirstMark Capital
306. FitBit
307. FITJOY
308. Flare Capital Partners
309. Flatiron Investors
310. Floodgate
311. Floreo
312. Florida Hospital
313. Flying Health
314. Focus DataScience
315. Force Over Mass Capital
316. Ford Motor Company
317. Forward Partners
318. Founder Collective
319. Founders Factory
320. Founders Fund
321. Founders Health
322. Fred Hutchinson Cancer Research Center
323. Freelands Ventures
324. Freestyle Capital
325. Frist Center for Autism and Innovation
326. Fruit Street
327. Frumtak Ventures
328. Fuerst Technology Innovations
329. Future.Health
330. FuturePeds
331. FWD Takaful
332. GAIA
333. Gait Up
334. GC VR Tracker Fund
335. GE Ventures
336. Gelt Venture Capital
337. Genentech, a subsidiary of Roche
338. General Catalyst
339. Gennev
340. Genoa Telepsychiatry
341. George Washington University School of Medicine
342. Georgian Partners
343. Giant Leap
344. Ginger
345. GlaxoSmithKline
346. Global Founders Capital
347. GlobalYeast
348. Go Clinic
349. Go Digital KSA
350. Golden Seeds
351. Google
352. Grammelot
353. GrayMatters Health
354. Great Heights Family Medicine
355. Greg Badros
356. Greycroft
357. GreyGreen
358. GrowX Venture Management
359. GSR Ventures
360. GuideWell Mutual Holding Corporation
361. Haas F1 Team
362. Habitual
363. Hanmi IT
364. Happify Health
365. Harbor Pacific Capital
366. Harrison Metal
367. Healios
368. Health Allliance Plan
369. Health Care Originals
370. Health Catalyst
371. Health Mates
372. Health Transformation Alliance
373. HealthPartners
374. HealthReveal
375. HealthSlate
376. HealthTap
377. HealthX Ventures
378. Healthy Trucking Association of America
379. Heart Foundation
380. Heartcore Capital
381. Helios Orion
382. HelloFresh
383. Highmark Health
384. Highmark Intera ctive
385. High-Tech Gründerfonds
386. Higi
387. Hikma Ventures
388. Hinduja Group
389. Hintsa Performance
390. Hospices Civils de Lyon
391. Hospital Universitario Reina Sofía
392. Hudson River Capital Partners
393. Human API
394. Humana
395. Hustle Fund
396. Hyde Park Angels
397. Hygieia
398. I Mercury Capital
399. I2A Fund
400. IBB Beteiligungsgesellschaft
401. iBionext
402. IBM
403. Idinvest Partners
404. IEEE
405. iFeel Labs
406. IIFL Select Equity Fund
407. i-Mercury Capital
408. Immortalana
409. IMPACT Accelerator
410. Impact First Investments
411. IMS Health
412. Incos Invest
413. Index Ventures
414. Initialized Capital
415. inMotion VR
416. Innogest Capital
417. Innovate Health Tech NYC
418. Innovate UK
419. Innovation Capital
420. Innovation Works
421. Innovationsstarter Fonds Hamburg
422. Institut de la Vision
423. Insulet
424. INTAGE Holdings
425. Intel Capital
426. Intermountain Healthcare
427. Intermountain Ventures
428. International Finance Corporation (IFC)
429. Intervest
430. Invest Detroit Ventures
431. Invitalia Ventures
432. Ironwood Pharmaceuticals
433. iSeed Ventures
434. iSono Health
435. Israel Innovation Authority
436. Itochu
437. ITOCHU Technology Ventures
438. Iwagin Jigyo Souzou Capital
439. JamJar Investments
440. Janssen Research & Development
441. JAZZ Venture Partners
442. Jett Capital Advisors
443. JOGO Health
444. John Hopki ns University
445. Johns Hopkins School of Hygiene and Public Health
446. Johnson & Johnson
447. Joint Academy
448. Joslin Diabetes Center
449. Joyable
450. Joyance Partners
451. Jumpstart Ventures
452. Juvenile Diabetes Research Foundation T1D fund
453. K Cube Ventures
454. K2 Investment Partners
455. KAC Health
456. Kaia Health
457. Kaiser Permanente Ventures
458. Kakao Ventures
459. Kapor Capital
460. Karuna Labs
461. Keio Innovation Initiative
462. Kelvi
463. Kentucky Science and Technology
464. Kentucky Science Center
465. Khosla Ventures
466. Kiio
467. King River Capital
468. King's College London
469. Kinnevik
470. Kinsa
471. Kleiner Perkins
472. Kleiner Perkins Caufield & Byers
473. KORE Digital Health Therapeutics
474. Korea Advanced Institute of Science and Technology
475. Koshidaka
476. KTB Network
477. Kurbo Health
478. Kurma Diagnostics
479. Kwit
480. Kyma Medical Technologies
481. KYT-Know Your Treatment
482. Laidir Foundation
483. Landmark Benefits
484. Lark Health
485. Launchpad Digital Health
486. Launchpad Venture Group
487. LB Investment
488. LBO France
489. Learn Capital
490. Leman Micro Devices
491. LEO Innovation Lab
492. Lief Therapeutics
493. Life Sciences Discovery Fund
494. LifeForce Capital
495. Lifeforce Ventures
496. Lifeline Ventures
497. LifeScan
498. LifeScan
499. Lifespot Health
500. Lifestyle & Wellness Medical Center
501. LifeWave Biomedical
502. Lightspeed Venture Partners
503. Limbix
504. LindaCare
505. LionBirds
506. Liquid 2 Ventures
507. Lirio
508. LiveBetter
509. Livongo Health
510. Louisiana Department of Health
511. Luminopia
512. Lumira Capital
513. LumiraDx
514. Lumosity
515. Lund University
516. Lux Capital
517. Luz Saude
518. Lyfebulb
519. M Ventures
520. M12
521. M3 Ventures
522. m8 Capital
523. Macadamian
524. Magellan Health
525. Mahana Therapeutics
526. MAIF Avenir
527. Mangrove Capital Partners
528. Manipal Education & Medical Group
529. Manipal Education and Medical Group
530. MAP Health Management
531. Map My Health
532. Maryland Technology Development Corporation (TEDCO)
533. MassChallenge
534. Maven Clinic
535. Maverick Ventures
536. Max Healthcare
537. Mayfield Fund
538. McLaren Racing
539. MDLIVE
540. MediPeace Vietnam
541. Medomnia
542. MedRhythms
543. MedTech Innovator
544. Medtronic
545. Meliora Technology
546. Melon Health
547. Memorado
548. Merck
549. Merck Global Health Innovation Fund
550. Merck Ventures
551. Mersey Care NHS Foundation Trust
552. Meru Health
553. metaMe
554. Mevoked
555. mHealth Technologies
556. Mid-Atlantic Telehealth Resource Center
557. MindBeacon Group
558. MindMaze
559. MindSciences
560. Mindset Health
561. MINES & Associates
562. Ministry of Health, Manatu Hauora
563. MIO Global
564. MIT Hacking Medicine
565. MIT Venture Mentoring Service
566. Mitsubishi UFJ Capital
567. Mizuho Capital
568. MJog
569. Mobio Technologies
570. Monarch Medical Technologies
571. Montage Ventures
572. Mori Trust
573. Morningside Group
574. Morningside Ventures
575. Murray-Bertron
576. My mhealth
577. MyLife ID
578. mySugr
579. Naluri
580. Naluri Hidup
581. Nanobiosym Diagnostics
582. Nanon
583. NantHealth
584. National Aeronautics and Space Administration
585. National Cancer Institute
586. National Cancer Research Institute
587. National Institute of Biomedical Imaging and Bioengineering
588. National Institute of Diabetes and Digestive and Kidney Diseases
589. National Institute of Health
590. National Institute of Mental Health and Neuro Sciences
591. National Institute on Drug Abuse (NIDA)
592. National Institutes of Health
593. National Institutes on Aging
594. National Multiple Sclerosis Society
595. National Rheumatoid Arthritis Society
596. National Science Foundation
597. Navitus Health Solutions
598. Nemaura Medical
599. neuraltrain
600. NeuroCure
601. NeuroMetrix
602. Neurotrack
603. New Enterprise Associates
604. New Mexico Retiree Health Care Authority (NMRHCA)
605. New World Ventures
606. Newsenselab
607. Newtopia
608. Nexeon MedSystems
609. NextGen Venture Partners
610. NGP Capital
611. NHL Alumni Association
612. NightWare
613. Nike
614. Nimble Ventures
615. Nimbus Synergies
616. Noaber Foundation
617. nOCD.
618. NODEHealth
619. Nokia Growth Partners
620. Noom
621. North Texas Angel Network
622. North York General Hospital
623. Northwell Ventures
624. Norwest Venture Partners
625. Norwich Ventures
626. Novant Health
627. Novartis
628. Novator Partners
629. Novo Nordisk
630. NOVOSI
631. Nueon
632. Nunaps
633. Nutrimental Healthcare
634. NuvoAir
635. Obvious Ventures
636. Ocean Azul Partners
637. Octopus Ventures
638. Oklahoma Life Science Fund
639. Omada Health
640. Omidyar Technology Ventures
641. OMRON Global
642. Oncology Care Home Health
643. Oncology Care Home Health Specialists
644. Onduo
645. Ontario Telemedicine (OTN)
646. Ontario Telemedicine Network
647. Open Medicine Institute
648. Optum Ventures
649. Oracle
650. Orexo
651. Orla DTx
652. Oscilloscape
653. OSF Ventures
654. Otsuka America
655. Otsuka Pharmaceutical
656. Oxford Academic Health Science Network
657. Oxford Finance
658. Oxford University
659. Pallasite Ventures
660. Palo Alto Health Sciences
661. Palo Alto Medical Foundation
662. Parasail Health
663. PatientsLikeMe
664. Payor Logic
665. PayPal
666. PBJ Capital
667. Pear Therapeutics
668. Pegasus Tech Ventures
669. Personal Health Solutions
670. Pfizer
671. Phenomenelle Angels
672. Philips
673. Pico Interactive
674. Pinetree capital
675. Pinterest
676. Pioneer Fund
677. Pittsburgh Life Sciences Greenhouse
678. Pixie Scientific
679. Pixvana
680. Plan International
681. Playground Global
682. Plug and Play Tech Center
683. PMV
684. Podimetrics
685. Pond Capital
686. POPS! Diabetes Care
687. Premera Blue Cross
688. Presence Capital
689. Prestige Health Choice
690. Prism Healthcare
691. Pritzker Group Venture Capital
692. Prognos Health
693. Progyny
694. Promus Ventures
695. Propeller Health
696. Prority Health
697. Proteus Digital Health
698. Prototron
699. Provenance Venture Forum
700. Providence Health & Services
701. Providence Ventures
702. Psious
703. Purdue University
704. PureTech Health
705. Qardio
706. Qatar Development Bank
707. Qatar Science & Technology Park
708. Qiming Venture Partners
709. Qualcomm Ventures
710. Quinze-Vingts National Ophthalmology Hospital
711. Quotas Beteiligungs
712. R7 Partners
713. Rally Health
714. RB Investments
715. ReachLink
716. Reaktor Ventures
717. Real Appeal
718. Recruit Strategic Partners
719. Red One Medical
720. RedBrick Health
721. Redmile Group
722. Redox
723. Reflectance Medical
724. RegenConBio
725. Renalis
726. ResApp Health
727. Research Foundation for The State University of New York
728. Research Institute of Sant Pau
729. Research Society for The Study of Diabetes in India (RSSDI)
730. Restore Health
731. Rethink Impact
732. Retrofit
733. Revon Systems
734. Rewire
735. RhythmiaBreath
736. Ridgefield Public Schools
737. RMDY Health
738. Roche
739. Rock Health
740. Romulus Capital
741. Rothenberg Ventures
742. RRE Ventures
743. S.R. One
744. Saama Capital India Advisors
745. Safar Partners
746. Safeguard Scientifics
747. Sagamok Anishnawbek
748. Saison Ventures
749. Salesforce
750. Salumedia
751. Samsung
752. Samsung Electronics
753. Samsung Health
754. Samsung Venture Investment
755. Sandoz
756. Sanitas
757. Sanner
758. Sanner Ventures
759. Sano Intelligence
760. Sanofi
761. Sapphire Ventures
762. Sarjan Health
763. SBRI Healthcare
764. Schoolhouse Partners
765. Schooner Consulting
766. SciFi VC
767. Scrum Ventures
768. Seattle Children’s Research Institute
769. Second Nature
770. Self Care Catalysts
771. selfit health
772. Selfit Medical
773. Selfridges
774. SENACTI
775. Sennheiser
776. Seoul National University Bundang Hospital
777. Sequoia Capital
778. Servier
779. ShapeUp
780. Sharecare
781. Shenzhen JRW Technology
782. Sherpa Capital
783. Shionogi
784. Shire
785. Shire Pharmaceuticals
786. Sidekick Health
787. Signia Venture Partners
788. Silicon Valley Bank
789. Silicon Valley TMS
790. SilverCloud Heath
791. Sino Portfolio International
792. Siren Care
793. Slow Ventures
794. Social Capital
795. Social Starts
796. Solera Health
797. Somatix
798. SOMPO Digital Lab
799. Sompo Japan Nipponkoa
800. Sonormed
801. Sony Innovation Fund
802. Sophia Bendz
803. SOS Ventures
804. Sosna + Co
805. Sound Life Sciences
806. Sozo Ventures
807. Sparknet (India) Marketing
808. Sparo
809. Spectrum Equity
810. Spire
811. Spotify
812. Spring Ridge Ventures
813. Sprint Accelerator
814. St. Joseph's Care Group
815. St. Jude Medical
816. St. Luke's Health System
817. St. Michael's Hospital
818. Stanford University School of Medicine
819. Stanley Park Ventures
820. Startmate
821. Startup Funding Club
822. StartUp Health
823. Startupbootcamp Digital Health Berlin
824. Stateline Angels
825. Steelcase
826. Storm Ventures
827. Stress Point Health
828. SUSMED
829. Sutter Health
830. SV Life Sciences
831. Sweet Capital
832. Swift Medical
833. Swing Therapeutics
834. Swiss Re
835. SyncMed
836. Synovation Medical Group
837. TALi Digital
838. Talkspace
839. Technology Development Fund (TDF)
840. Techstars
841. Teijin
842. Teladoc Health
843. Telcare
844. Telefonica
845. Temasek
846. Temasek Holdings
847. The Aplastic Anemia & MDS International Foundation
848. The Canadian Tire Wickenheiser World Female Hockey Festival
849. The Cancer Research Collaboration
850. The Carlyle Group
851. The Chernin Group
852. The Learning Corp
853. The Research Foundation for The State University of New York
854. The Robotics Hub
855. The Sync Project
856. The Valley Fund
857. The Venture Reality Fund
858. The Vertical Group
859. TheraTec
860. Think Patients
861. Think.Health
862. Thrive Capital
863. Tiatros
864. TiE Boston Angels
865. Tilak Healthcare
866. Tipp ecanoe County Government
867. Tokyo Century
868. Tower Capital Partners
869. Train 24/8
870. TransLink Capital
871. TreeHouse Health
872. Trend Forward Capital
873. TrialSpark
874. TriplePoint Capital
875. TriplePoint Ventures
876. Triumf Health
877. True Ventures
878. True Wealth Ventures
879. TT Capital Partners
880. Tuesday Capital
881. Turnaround Health
882. Twine Health
883. Twitter
884. U.S. Department of Veteran Affairs
885. U.S. Venture Partners
886. UCB
887. Ultra Testing
888. Uncork Capital
889. Unique Nutrition Solutions
890. United Healthcare
891. University Medical Center Goettingen
892. University of Bern
893. University of California
894. University of California Davis
895. University of Hamburg
896. University of London
897. University of Lubeck
898. University of Maryland
899. University of Massachusetts Medical School
900. University of Michigan
901. University of Missouri
902. University of Nebraska
903. University of Nebraska Medical Center
904. University of New York
905. University of North Carolina
906. University of Oxford
907. University of Pennsylvania
908. University of Rochester
909. University of Texas at Dallas
910. University of Texas Southwestern Medical School
911. University of Washington
912. UpLift Health
913. UPMC Enterprises
914. VA Palo Alto Health Care System (VAPAHCS)
915. Valerio Rosso
916. Valeritas Holdings
917. Validic
918. Vanguard Medical Group
919. Venrock
920. Venture Kick
921. Verily Life Sciences
922. Vertical Group
923. Vesalius Biocapital
924. Vheda Health
925. Vida Health
926. Vigo
927. Village Global
928. Vimeo
929. Virgin Atlantic
930. Virgin Pulse
931. Virta Health
932. VirtualScopics
933. Virtue Health
934. Vitadio
935. Vital Art and Science
936. Vital Labs
937. Vitality Group
938. Vivid Vision
939. VNR Vignana Jyothi Institute of Engineering and Technology
940. Volar Health
941. Voluntis
942. VSP Vision Care
943. Wake Forest University
944. Wakestream Ventures
945. Wanxiang America
946. Washington State Department of Health
947. Washington University School of Medicine
948. Wayra
949. WEA Trust
950. Welkin Health
951. Wellbe
952. WellDoc
953. WellDyneRx
954. Wellington Management
955. Wellthy Therapeutics
956. Welltoc
957. Welltrinsic Sleep Network
958. West Coast Primary Health Organization
959. Wicks Digital Health
960. Wildflower Brands
961. William Morris Endeavor
962. William Osler Health System
963. Windham Venture Partners
964. Wisconsin Investment Partners
965. Withings
966. Wonderfull Wellness
967. Wonju Severance Christian Hospital
968. Workday Ventures
969. Workit Health
970. World Health Organization
971. WP Global Partners
972. WTF Health
973. XING
974. Xtreme Labs
975. Y Combinator
976. Yale University
977. Z3VR
978. Zaffre Investments
979. Zillion
980. ZOLL Medical
981. Zyus


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Product Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Prescription Requirement
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4 Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutics Solutions
4.6. Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
4.7. Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
4.8. Tree Map Representation: Analysis by Therapeutic Area and Company Size
4.9. World Map Representation: Analysis of Regional Activity
4.10. Digital Therapeutics: Information on Additional Companies
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Key Therapeutic Areas
5.4.1. Cardiovascular Disorders
5.4.1.1. Product Competitiveness Analysis
5.4.2. Mental Health Problems
5.4.2.1. Product Competitiveness Analysis
5.4.3. Metabolic Disorders
5.4.3.1. Product Competitiveness Analysis
5.4.4. Neurological Disorders
5.4.4.1. Product Competitiveness Analysis
5.4.5. Substance Use Disorders
5.4.5.1. Product Competitiveness Analysis
5.4.6. Other Therapeutic Areas
5.4.6.1. Product Competitiveness Analysis
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Mindmaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled and Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Players: Analysis by Number of Registered Trials
7.3.8 Leading Digital Therapeutic Solutions: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Geographical Analysis by Number of Clinical Trials
7.3.12. Geographical Analysis by Trial Recruitment Status
7.3.13. Geographical Analysis by Enrolled Patient Population
7.4. Clinical End-Points Analysis
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Digital Therapeutics: Funding and Investment Analysis
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Therapy
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Geography
8.3.7. Most Active Players: Analysis by Number of Funding Instances
8.3.8. Most Active Players: Analysis by Amount of Funding
8.3.9. Most Active Investors: Analysis by Number of Instances
8.4 Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: Recent Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Type of Partnership and Year of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Type of Partner and Year of Partnership
9.3.3.2. Analysis by Type of Partner and Type of Partnership
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Therapy and Type of Partnership
9.3.4.2. Analysis by Type of Therapy and Type of Partner
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Therapeutic Area and Year of Partnership
9.3.5.2 Analysis by Therapeutic Area and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models and Pricing Strategies
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3 Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2020-2030
12.4. Global Digital Therapeutics Market: Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2020-2030
12.4.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030
12.4.3. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030
12.4.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030
12.4.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030
12.4.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2020-2030
12.5. Global Digital Therapeutics Market: Distribution by Purpose of Solution
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030
12.6. Global Digital Therapeutics Market: Distribution by Type of Therapy
12.6.1 Digital Therapeutics Market for Curative Therapy, 2020-2030
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2020-2030
12.7. Global Digital Therapeutics Market: Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030
12.7.2. Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030
12.8. Global Digital Therapeutics Market: Distribution by Therapeutic Area
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030
12.8.2. Digital Therapeutics Market for Chronic Pain, 2020-2030
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2020-2030
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2020-2030
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2020-2030
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2020-2030
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2020-2030
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2020-2030
12.8.9. Digital Therapeutics Market for Other Disorders, 2020-2030
12.9. Global Digital Therapeutics Market: Distribution by Geography
12.9.1 Digital Therapeutics Market in North America, 2020-2030
12.9.1.1 Digital Therapeutics Market in the US, 2020-2030
12.9.1.2 Digital Therapeutics Market in Canada, 2020-2030
12.9.2 Digital Therapeutics Market in Europe, 2020-2030
12.9.2.1. Digital Therapeutics Market in France, 2020-2030
12.9.2.2. Digital Therapeutics Market in Germany, 2020-2030
12.9.2.3. Digital Therapeutics Market in Italy, 2020-2030
12.9.2.4. Digital Therapeutics Market in Spain, 2020-2030
12.9.2.5. Digital Therapeutics Market in the UK, 2020-2030
12.9.2.6. Digital Therapeutics Market in Rest of Europe, 2020-2030
12.9.3. Digital Therapeutics Market in Asia-Pacific, 2020-2030
12.9.3.1. Digital Therapeutics Market in Australia, 2020-2030
12.9.3.2. Digital Therapeutics Market in China, 2020-2030
12.9.3.3. Digital Therapeutics Market in India, 2020-2030
12.9.3.4. Digital Therapeutics Market in Japan, 2020-2030
12.9.3.5. Digital Therapeutics Market in South Korea, 2020-2030
12.9.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030
12.9.4. Digital Therapeutics Market in Rest of the World, 2020-2030
13. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
13.1. Chapter Overview
13.2. Impact of Coronavirus Pandemic on Digital Therapeutics
13.2.1. Impact on Future Market Opportunity for Digital Therapeutic Solutions Market
13.3. Recuperative Strategies for Developer Businesses
13.3.1. Strategies for Implementation in the Short / Mid Term
13.3.2. Strategies for Implementation in the Long Term
14. REMOTE DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS
14.1. Chapter Overview
14.2. An Introduction to Remote Digital Monitoring / Diagnostic Solutions
14.3. Remote Digital Monitoring / Diagnostic Solutions: Overall Market Landscape
14.3.1. Analysis by Status of Development
14.3.2. Analysis by Type of Solution
14.3.3. Analysis by Target Disease Indication(s)
14.3.4. Analysis by Therapeutic Area
14.3.5. Grid Representation: Analysis by Status of Development, Type of Solution, and Therapeutic Area
14.4. Remote Digital Monitoring / Diagnostic Solutions: List of Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters
14.5. Remote Digital Monitoring / Diagnostic Solutions: Company Profiles
14.5.1. AliveCor
14.5.1.1. Company Snapshot
14.5.1.2. Product Portfolio
14.5.1.3. Recent Developments and Future Outlook
14.5.2. Bioserenity
14.5.2.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook
14.5.3. Cue
14.5.3.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook
14.5.4. Kinsa
14.5.4.1. Company Snapshot
14.5.4.2. Product Portfolio
14.5.4.3. Recent Developments and Future Outlook
14.6. Remote Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis
14.6.1. Types of Funding
14.6.2. Remote Digital Monitoring / Diagnostic Solutions: List of Funding and Investments
14.6.2.1. Analysis by Number of Funding Instances
14.6.2.2. Analysis by Amount Invested
14.6.2.3. Analysis by Type of Funding
14.6.2.4. Most Active Players: Analysis by Number of Funding Instances
14.6.2.5. Most Active Players: Analysis by Amount Invested
14.6.2.6. Most Active Investors: Analysis by Number of Funding Instances
14.7. Concluding Remarks
15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors
15.2.1. Strengths
15.2.2. Weaknesses
15.2.3. Opportunities
15.2.4. Threats
16. DIGITAL SOLUTIONS: RECENT TRENDS AND FUTURE OPPORTUNITIES
16.1. Chapter Overview
16.2. Prevalent Trends Related to Digital Therapeutics
16.2.1. Emerging Focus Areas
16.2.2. Key Historical Trends
16.2.3. Geographical Distribution of Activity
16.3. Trends Shaping the Future of Digital Therapeutics
16.3.1. Digital Solutions Closing the Digital Gap
16.3.2. Increasing Focus on Patient Centric Models
16.3.3. Applicability across a Variety of Disease Indications
16.3.4. Increasing Emphasis on Real-World Evidence in Research and Development
16.3.5. Advances in IT and Computing Power to Foster Future Innovation
16.4. Improving the Future Health: Opportunities Beyond Digital Therapeutics
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Vida Health
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer
17.3. Canary Health
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Adam Kaufman, Chief Executive Officer
17.4. Floreo
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Vijay Ravidran, Chief Executive Officer
17.5. Somatix
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Eran Ofir, Chief Executive Officer
17.6. Tilak Healthcare
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Edouard Gasser, Chief Executive Officer
17.7. Wellthy Therapeutics
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Palakh R Saraogi, Vice President Marketing, Arani Sarkra, Senior Manager Consumer Marketing, and Yolande D’Mello, Marketing and Public Relations
17.8. Voluntis
17.8.1. Company Snapshot
17.8.2. Interview Transcript: Amelie Janson, Communications Manager
17.9. Anonymous
17.9.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Major Causes for Chronic Diseases
Figure 3.2 Historical Timeline of Digital Health: Analysis of Google Trends
Figure 3.3 Internet of Things: General Framework
Figure 3.4 Internet of Things: Applications in Healthcare
Figure 3.5 Prescription Digital Therapeutics: Process Map
Figure 3.6 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 4.1 Digital Therapeutics: Distribution by Status of Development
Figure 4.2 Digital Therapeutics: Distribution by Approval Year
Figure 4.3 Digital Therapeutics: Distribution by Type of Solution
Figure 4.4 Digital Therapeutics: Distribution by Type of Therapy
Figure 4.5 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.6 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Figure 4.7 Digital Therapeutics: Distribution by Target Indication(s)
Figure 4.8 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.9 Digital Therapeutics: Distribution by Target Population
Figure 4.10 Digital Therapeutics: Distribution by Prescription Requirement
Figure 4.11 Digital Therapeutics: Distribution by Duration of Course
Figure 4.12 Digital Therapeutics: Distribution by Cost of Solution
Figure 4.13 Digital Therapeutics Developers: Distribution by Year of Establishment
Figure 4.14 Digital Therapeutics Developers: Distribution by Company Size
Figure 4.15 Digital Therapeutics Developers: Distribution by Business Model Used
Figure 4.16 Digital Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.17 Leading Developers: Analysis by Number of Digital Therapeutics Solutions
Figure 4.18 Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
Figure 4.19 Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
Figure 4.20 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Figure 4.21 World Map Representation: Regional Activity of Developers
Figure 5.1 Cardiovascular Disorders: Shift in Trends (2018 to 2020)
Figure 5.2 Product Competitiveness Analysis: Cardiovascular Disorders
Figure 5.3 Mental Health Problems: Shift in Trends (2018 to 2020)
Figure 5.4 Product Competitiveness Analysis: Mental Health Problems
Figure 5.5 Metabolic Disorders: Shift in Trends (2018 to 2020)
Figure 5.6 Product Competitiveness Analysis: Metabolic Disorders
Figure 5.7 Neurological Disorders: Shift in Trends (2018 to 2020)
Figure 5.8 Product Competitiveness Analysis: Neurological Disorders
Figure 5.9 Substance Use Disorders: Shift in Trends (2018 to 2020)
Figure 5.10 Product Competitiveness Analysis: Substance Use Disorders
Figure 5.11 Other Therapeutic Areas: Shift in Trends (2018 to 2020)
Figure 5.12 Product Competitiveness Analysis: Other Therapeutic Areas
Figure 6.1 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 6.2 WellDoc: Key Benefits of Diabetes Management Program
Figure 6.3 Wellthy Therapeutics: Diabetes Program
Figure 7.1 Key Methods to Validate Digital Therapeutic Solutions
Figure 7.2 Clinical Trial Analysis: Scope and Methodology
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, Pre-2011-2020
Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.8 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.10 Clinical Trial Analysis: Leading Industry Players
Figure 7.11 Clinical Trial Analysis: Leading Digital Therapeutic Solutions
Figure 7.12 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Therapeutic Area
Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Number of Patients Enrolled (in thousands) for Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.20 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Figure 7.21 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Figure 8.1 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Pre-2014-June-2020
Figure 8.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-June 2020
Figure 8.3 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-June 2020 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-June 2020
Figure 8.5 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding Pre-2014-June 2020
Figure 8.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-June 2020 (USD Million)
Figure 8.7 Funding and Investment Analysis: Year-Wise Distribution of Amount Invested and Type of Funding, Pre-2014-June 2020 (USD Million)
Figure 8.8 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-June 2020 (USD Million)
Figure 8.9 Funding and Investment Analysis: Distribution by Instances and Amount Invested by Type of Therapy, Pre-2014-June 2020 (USD Million)
Figure 8.10 Funding and Investment Analysis: Year-Wise Distribution of Instances by Type of Therapy, Pre-2014-June 2020
Figure 8.11 Funding and Investment Analysis: Cumulative Amount Invested (USD Million) by Type of Therapy, Pre-2014-June 2020
Figure 8.12 Funding and Investment Analysis: Distribution by Therapeutic Area, Pre-2014-June 2020
Figure 8.13 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, Pre-2014-June2020 (USD Million)
Figure 8.14 Funding and Investment Analysis: Distribution by Geography
Figure 8.15 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-June 2020
Figure 8.16 Most Active Players: Distribution by Number of Funding Instances, Pre-2014-June 2020
Figure 8.17 Most Active Players: Distribution by Amount Raised (USD Million), Pre-2014-June 2020
Figure 8.17 Most Active Investors: Distribution by Number of Funding Instances
Figure 8.18 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2013-May 2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Therapy
Figure 9.10 Partnerships and Collaborations: Distribution by Type of Therapy and Type of Partnership
Figure 9.11 Partnerships and Collaborations: Distribution by Distribution by Type of Therapy and Type of Partner
Figure 9.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 9.14 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Figure 9.15 Most Active Players: Distribution by Number of Partnerships
Figure 9.16 Partnerships and Collaborations: Regional Distribution
Figure 9.17 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Go-to-Market Strategy: Commonly Used Social Media Platforms
Figure 10.2 Go-to-Market Strategy: Online / Print Media Platforms
Figure 10.3 Go-to-Market Strategy: Promotional Activities through Official Websites
Figure 10.4 Go-to-Market Strategy: Different Business Models Adopted
Figure 10.5 Go-to-Market Strategy: Promotional Activities through Product Websites
Figure 10.6 Go-to-Market Strategy: Key Marketing Strategies for New Entrants
Figure 10.7 Go-to-Market Strategy: Industry Stakeholder Opinions
Figure 11.1 Digital Therapeutics: Bowman Clock Pricing Strategy Matrix
Figure 11.2 Digital Therapeutics: Bowman Clock Pricing Strategy Graphical Interpretation
Figure 12.1 Overall Digital Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Figure 12.2 Global Digital Therapeutics Market: Distribution by Type of Solution, 2020 and 2030
Figure 12.3 Digital Therapeutics Market for Standalone Software Applications, 2020-2030 (USD Million)
Figure 12.4 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030 (USD Million)
Figure 12.5 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030 (USD Million)
Figure 12.6 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030 (USD Million)
Figure 12.7 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030 (USD Million)
Figure 12.8 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030 (USD Million)
Figure 12.9 Digital Therapeutics Market for Other Type of Solutions, 2020-2030 (USD Million)
Figure 12.10 Global Digital Therapeutics Market: Distribution by Purpose of Solution, 2020 and 2030
Figure 12.11 Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030 (USD Million)
Figure 12.12 Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030 (USD Million)
Figure 12.13 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2020 and 2030
Figure 12.14 Digital Therapeutics Market for Curative Therapy, 2020-2030 (USD Million)
Figure 12.15 Digital Therapeutics Market for Preventive Therapy, 2020-2030 (USD Million)
Figure 12.16 Global Digital Therapeutics Market: Distribution by Business Model, 2020 and 2030
Figure 12.17 Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030 (USD Million)
Figure 12.18 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030 (USD Million)
Figure 12.19 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2020 and 2030
Figure 12.20 Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030 (USD Million)
Figure 12.21 Digital Therapeutics Market for Chronic Pain, 2020-2030 (USD Million)
Figure 12.22 Digital Therapeutics Market for Mental Health Problems, 2020-2030 (USD Million)
Figure 12.23 Digital Therapeutics Market for Metabolic Disorders, 2020-2030 (USD Million)
Figure 12.24 Digital Therapeutics Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 12.25 Digital Therapeutics Market for Respiratory Disorders, 2020-2030 (USD Million)
Figure 12.26 Digital Therapeutics Market for Sleep Disorders, 2020-2030 (USD Million)
Figure 12.27 Digital Therapeutics Market for Substance Use Disorders, 2020-2030 (USD Million)
Figure 12.28 Digital Therapeutics Market for Other Disorders, 2020-2030 (USD Million)
Figure 12.29 Global Digital Therapeutics Market: Distribution by Geography, 2020 and 2030
Figure 12.30 Digital Therapeutics Market in North America, 2020-2030 (USD Million)
Figure 12.31 Digital Therapeutics Market in the US, 2020-2030 (USD Million)
Figure 12.32 Digital Therapeutics Market in Canada, 2020-2030 (USD Million)
Figure 12.33 Digital Therapeutics Market in Europe, 2020-2030 (USD Million)
Figure 12.34 Digital Therapeutics Market in France, 2020-2030 (USD Million)
Figure 12.35 Digital Therapeutics Market in Germany, 2020-2030 (USD Million)
Figure 12.36 Digital Therapeutics Market in Italy, 2020-2030 (USD Million)
Figure 12.37 Digital Therapeutics Market in Spain, 2020-2030 (USD Million)
Figure 12.38 Digital Therapeutics Market in the UK, 2020-2030 (USD Million)
Figure 12.39 Digital Therapeutics Market in Rest of Europe, 2020-2030 (USD Million)
Figure 12.40 Digital Therapeutics Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 12.41 Digital Therapeutics Market in Australia, 2020-2030 (USD Million)
Figure 12.42 Digital Therapeutics Market in China, 2020-2030 (USD Million)
Figure 12.43 Digital Therapeutics Market in India, 2020-2030 (USD Million)
Figure 12.44 Digital Therapeutics Market in Japan, 2020-2030 (USD Million)
Figure 12.45 Digital Therapeutics Market in South Korea, 2020-2030 (USD Million)
Figure 12.46 Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030 (USD Million)
Figure 12.47 Digital Therapeutics Market in Rest of the World, 2020-2030 (USD Million)
Figure 12.48 Global Digital Therapeutics Market, 2020-2030: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 13.1 Global Digital Therapeutics Market 2020-2030: COVID-19 Impact Informed Scenario (USD Billion)
Figure 14.1 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Figure 14.2 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Figure 14.3 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Target Disease Indication
Figure 14.4 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Figure 14.5 Grid Representation: Distribution by Status of Development, Type of Solution, and Therapeutic Area
Figure 14.6 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Year of Establishment
Figure 14.7 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Company Size
Figure 14.8 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Location of Headquarters
Figure 14.9 AliveCor: Benefits of Kardia
Figure 14.10 Cue: Key Elements of Digital Monitoring / Diagnostic Solutions
Figure 14.11 Kinsa: Product Portfolio
Figure 14.12 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Number of Funding Instances by Year
Figure 14.13 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested (USD Million)
Figure 14.14 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Instances by Type of Funding
Figure 14.15 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 14.16 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Funding Instances
Figure 14.17 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested (USD Million)
Figure 14.18 Remote Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Funding Instances
Figure 15.1 Digital Therapeutics SWOT Analysis: Overview
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Emerging Focus Areas: Google News
Figure 16.2 Digital Therapeutics: Analysis of Google Trends
Figure 16.3 Geographical Activity: Analysis of Google Trends
Figure 16.4 Digital Health: Opportunities beyond Digital Therapeutics
LIST OF TABLES
Table 4.1 Digital Therapeutics: Information on Status of Development and Launch Year
Table 4.2 Digital Therapeutics: Information on Type of Solution
Table 4.3 Digital Therapeutics: Information on Type of Therapy and Purpose of Solution
Table 4.4 Digital Therapeutics: Information on Information on Target Indication(s), Therapeutic Area and Target Population
Table 4.5 Digital Therapeutic Solutions: Information on Prescription Requirement, Duration of Course and Cost of Solution
Table 4.4 Digital Therapeutics: List of Developers
Table 6.1 Digital Therapeutics: List of Companies Profiled
Table 6.2 Akili Interactive: Company Snapshot
Table 6.3 Akili Interactive: Digital Therapeutic Solutions Portfolio
Table 6.4 Akili Interactive: Recent Developments and Future Outlook
Table 6.5 Big Health: Company Snapshot
Table 6.6 Big Health: Digital Therapeutic Solutions Portfolio
Table 6.7 Big Health: Recent Developments and Future Outlook
Table 6.8 dreem: Company Snapshot
Table 6.9 dreem: Digital Therapeutic Solutions Portfolio
Table 6.10 dreem: Recent Developments and Future Outlook
Table 6.11 Kaia Health: Company Snapshot
Table 6.12 Kaia Health: Digital Therapeutic Solutions Portfolio
Table 6.13 Kaia Health: Recent Developments and Future Outlook
Table 6.14 Mindmaze: Company Snapshot
Table 6.15 Mindmaze: Digital Therapeutic Solutions Portfolio
Table 6.16 Omada Health: Company Snapshot
Table 6.17 Omada Health: Digital Therapeutic Solutions Portfolio
Table 6.18 Omada Health: Recent Developments and Future Outlook
Table 6.19 Pear Therapeutics: Company Snapshot
Table 6.20 Pear Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.21 Pear Therapeutics: Recent Developments and Future Outlook
Table 6.22 Vida Health: Company Snapshot
Table 6.23 Vida Health: Digital Therapeutic Solutions Portfolio
Table 6.24 Vida Health: Recent Developments and Future Outlook
Table 6.25 Voluntis: Company Snapshot
Table 6.26 Voluntis: Digital Therapeutic Solutions Portfolio
Table 6.27 Voluntis: Recent Developments and Future Outlook
Table 6.28 Welldoc: Company Snapshot
Table 6.29 Welldoc: Digital Therapeutic Solutions Portfolio
Table 6.30 Welldoc: Recent Developments and Future Outlook
Table 6.31 Wellthy Therapeutics: Company Snapshot
Table 6.32 Wellthy Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.33 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 8.1 Digital Therapeutics: Funding and Investments, Information on Year of Investment, Type of Funding, Amount and Investor, till June 2020
Table 8.2 Digital Therapeutics: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Therapy, and Therapeutic Area
Table 9.1 Digital Therapeutics: List of Collaborations, till May 2020
Table 9.2 Digital Therapeutics: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise), till May 2020
Table 10.1 Digital Therapeutics: Summary of Marketing Strategies
Table 10.2 Go-to-Market Strategy: Product Specific Websites
Table 14.1 Remote Digital Monitoring / Diagnostic Solutions: List of Solutions
Table 14.2 Remote Digital Monitoring / Diagnostic Solutions: Information on Type of Solution
Table 14.3 Remote Digital Monitoring / Diagnostic Solutions: Information on Primary Disease Indication, Therapeutic Area and Diagnosis Indicators
Table 14.4 Remote Digital Monitoring / Diagnostic Solutions: List of Developers
Table 14.5 AliveCor: Company Snapshot
Table 14.6 AliveCor: Recent Developments and Future Outlook
Table 14.7 BioSerenity: Company Snapshot
Table 14.8 BioSerenity: Recent Developments and Future Outlook
Table 14.9 Cue: Company Snapshot
Table 14.10 Kinsa: Company Snapshot
Table 14.11 Kinsa: Recent Developments and Future Outlook
Table 14.12 Remote Digital Monitoring / Diagnostic Solutions: Funding and Investments
Table 14.13 Remote Digital Monitoring / Diagnostic Solutions: Summary of Investments
Table 17.1 Vida Health: Company Snapshot
Table 17.2 Canary Health: Company Snapshot
Table 17.3 Floreo: Company Snapshot
Table 17.4 Somatix: Company Snapshot
Table 17.5 Tilak Healthcare: Company Snapshot
Table 17.6 Wellthy Therapeutics: Company Snapshot
Table 17.7 Voluntis: Company Snapshot
Table 18.1 Digital Therapeutics: Distribution by Status of Development
Table 18.2 Digital Therapeutics: Distribution by Type of Solution
Table 18.3 Digital Therapeutics: Distribution by Type of Therapy
Table 18.4 Digital Therapeutics: Distribution by Purpose of Solution
Table 18.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Table 18.6 Digital Therapeutics: Distribution by Target Indication(s)
Table 18.7 Digital Therapeutics: Distribution by Therapeutic Area
Table 18.8 Digital Therapeutics: Distribution by Target Population
Table 18.9 Digital Therapeutics: Distribution by Prescription Requirement
Table 18.10 Digital Therapeutics: Distribution by Duration of Course
Table 18.11 Digital Therapeutics: Distribution by Cost of Solution
Table 18.12 Digital Therapeutics Developers: Distribution by Year of Establishment
Table 18.13 Digital Therapeutics Developers: Distribution by Company Size
Table 18.14 Digital Therapeutics Developers: Distribution by Business Model Used
Table 18.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Table 18.16 Leading Developers: Analysis by Number of Digital Therapeutics Solutions
Table 18.17 Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
Table 18.18 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Table 18.19 World Map Representation: Regional Activity of Developers
Table 18.20 Cardiovascular Disorders: Shift in Trends (2018 to 2020)
Table 18.21 Mental Health Problems: Shift in Trends (2018 to 2020)
Table 18.22 Metabolic Disorders: Shift in Trends (2018 to 2020)
Table 18.23 Neurological Disorders: Shift in Trends (2018 to 2020)
Table 18.24 Substance Use Disorders: Shift in Trends (2018 to 2020)
Table 18.25 Other Therapeutic Areas: Shift in Trends (2018 to 2020)
Table 18.26 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Table 18.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 18.28 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, Pre-2011-2020
Table 18.29 Clinical Trial Analysis: Distribution by Study Design
Table 18.30 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 18.31 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 18.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 18.33 Clinical Trial Analysis: Leading Industry Players
Table 18.34 Clinical Trial Analysis: Leading Digital Therapeutic Solutions
Table 18.35 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 18.36 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 18.37 Clinical Trial Analysis: Distribution by Number of Patients Enrollment and Therapeutic Area
Table 18.38 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollments (in thousands) for Popular Therapeutic Areas
Table 18.39 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 18.40 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 18.41 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 18.42 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Pre-2014-June-2020
Table 18.43 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-June 2020
Table 18.44 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-June 2020 (USD Million)
Table 18.45 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-June 2020
Table 18.46 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding, Pre-2014-June 2020
Table 18.47 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-June 2020 (USD Million)
Table 18.48 Funding and Investment Analysis: Year-Wise Distribution of Amount Invested and Type of Funding, Pre-2014-June 2020 (USD Million)
Table 18.49 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-June 2020 (USD Million)
Table 18.50 Funding and Investment Analysis: Distribution by Instances and Amount Invested by Type of Therapy, Pre-2014-June 2020 (USD Million)
Table 18.51 Funding and Investment Analysis: Year-Wise Distribution of Instances by Type of Therapy, Pre-2014-June 2020
Table 18.52 Funding and Investment Analysis: Cumulative Amount Invested (USD Million) by Type of Therapy, Pre-2014-June 2020
Table 18.53 Funding and Investment Analysis: Distribution by Therapeutic Area, Pre-2014-June 2020 (USD Million)
Table 18.54 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, Pre-2014-April 2020 (USD Million)
Table 18.55 Funding and Investment Analysis: Distribution by Geography
Table 18.56 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-June 2020
Table 18.57 Most Active Players: Distribution by Number of Funding, Pre-2014-June 2020
Table 18.58 Most Active Players: Distribution by Number of Amount Raised (USD Million), Pre-2014-June 2020
Table 18.59 Most Active Investors: Distribution by Number of Funding Instances
Table 18.60 Funding and Investment Summary, Pre-2014-June 2020 (USD Million)
Table 18.61 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2014-May 2020
Table 18.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.63 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 18.64 Partnerships and Collaborations: Distribution by Type of Partnership and Partner
Table 18.65 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.66 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 18.67 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Table 18.68 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 18.69 Partnerships and Collaborations: Distribution by Type of Therapy
Table 18.70 Partnerships and Collaborations: Distribution by Type of Therapy and Type of Partnership
Table 18.71 Partnerships and Collaborations: Distribution by Distribution by Type of Therapy and Type of Partner
Table 18.72 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 18.73 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 18.74 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Table 18.75 Most Active Players: Distribution by Number of Partnerships
Table 18.76 Partnerships and Collaborations: Regional Distribution
Table 18.77 Partnerships and Collaborations: Country-Wise Distribution
Table 18.78 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 18.79 Go-to-Market Strategy: Commonly Used Social Media Platforms
Table 18.80 Go-to-Market Strategy: Online / Print Media
Table 18.81 Go-to-Market Strategy: Promotional Activities through Official Websites
Table 18.82 Go-to-Market Strategy: Different Business Models Adopted
Table 18.83 Go-to-Market Strategy: Promotional Activities through Product Websites
Table 18.84 Global Digital Therapeutics Market, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.85 Global Digital Therapeutics Market: Distribution by Type of Solution, 2020 and 2030
Table 18.86 Digital Therapeutics Market for Standalone Software Applications, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.87 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.88 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.89 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.90 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.91 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.92 Digital Therapeutics Market for Other Type of Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.93 Global Digital Therapeutics Market: Distribution by Purpose of Solution, 2020 and 2030
Table 18.94 Digital Therapeutics Market for Medication Replacement Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.95 Digital Therapeutics Market for Medication Augmentation Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.96 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2020 and 2030
Table 18.97 Digital Therapeutics Market for Curative Therapy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.98 Digital Therapeutics Market for Preventive Therapy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.99 Global Digital Therapeutics Market: Distribution by Business Model, 2020 and 2030
Table 18.100 Digital Therapeutics Market for B2C Model (Patients and, Caregivers), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.101 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.102 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2020 and 2030
Table 18.103 Digital Therapeutics Market for Cardiovascular Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.104 Digital Therapeutics Market for Chronic Pain, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.105 Digital Therapeutics Market for Mental Health Problems, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.106 Digital Therapeutics Market for Metabolic Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.107 Digital Therapeutics Market for Neurological Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.108 Digital Therapeutics Market for Respiratory Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.109 Digital Therapeutics Market for Sleep Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.110 Digital Therapeutics Market for Substance Use Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.111 Digital Therapeutics Market for Other Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.112 Global Digital Therapeutics Market: Distribution by Geography, 2020 and 2030
Table 18.113 Digital Therapeutics Market in North America, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.114 Digital Therapeutics Market in the US, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.115 Digital Therapeutics Market in Canada, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.116 Digital Therapeutics Market in Europe, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.117 Digital Therapeutics Market in France, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.118 Digital Therapeutics Market in Germany, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.119 Digital Therapeutics Market in Italy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.120 Digital Therapeutics Market in Spain, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.121 Digital Therapeutics Market in the UK, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.122 Digital Therapeutics Market in Rest of Europe, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.123 Digital Therapeutics Market in Asia-Pacific, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.124 Digital Therapeutics Market in Australia, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.125 Digital Therapeutics Market in China, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.126 Digital Therapeutics Market in India, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.127 Digital Therapeutics Market in Japan, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.128 Digital Therapeutics Market in South Korea, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.129 Digital Therapeutics Market in Rest of Asia-Pacific, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.130 Digital Therapeutics Market in Rest of the World, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.131 Digital Therapeutics Market 2030-2030: Conservative, Base and Optimistic Scenarios: COVID-19 Impact Informed Scenario (USD Billion)
Table 18.132 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Table 18.133 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Table 18.134 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Target Disease Indication
Table 18.135 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Table 18.136 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Year of Establishment
Table 18.137 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Company Size
Table 18.138 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Location of Headquarters
Table 18.139 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Number of Instances by Year
Table 18.140 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested (USD Million)
Table 18.141 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Instances by Type of Funding
Table 18.142 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 18.143 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Funding Instances
Table 18.144 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested (USD Million)
Table 18.145 Remote Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Funding Instances

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook